SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
GONE BUT NOT FORGOTTEN: HCV AFTER DIRECT-ACTING ANTIVIRAL THERAPY
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
INFERIORITY OF SHORT DURATION SOFOSBUVIR-VELPATASVIR FOR RECENT HCV (REACT STUDY) (ABSTRACT
121)
Gail Matthews
Kirby Institute, Sydney, Australia
INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS (ABSTRACT
122)
Javier Cepeda
University of California San Diego, LA JOLLA, CA, USA
LARGE HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS, WEST VIRGINIA, 2018–2019 (ABSTRACT
123)
Robert Paul McClung
Centers for Disease Control and Prevention, Atlanta, GA, USA
HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION (ABSTRACT
124)
Jelle Koopsen
Amsterdam University Medical Center, Amsterdam, Netherlands
NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE (ABSTRACT
125)
Linda M Styer
New York State Department of Health, Albany, NY, USA
HEPATOCELLULAR CARCINOMA RISK AMONG PERSONS WITH HIV IN NORTH AMERICA, 1996-2015 (ABSTRACT
126)
Jing Sun
Johns Hopkins University, Baltimore, MD, USA
HIV/HCV VS HCV: PLASMA AND LIVER VIRAL DYNAMICS AND IP-10 LEVELS (ABSTRACT
127)
Ashwin Balagopal
Johns Hopkins University, Baltimore, MD, USA
CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (ABSTRACT
128)
Lindsay T Fourman
Massachusetts General Hospital, Boston, MA, USA
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
9 of
9
|
